O estado da arte das síndromes autoinflamatórias associadas à criopirina
The state of the art of cryopyrin-associated periodic syndromes
Katharina Ruth Pagotto Betzler; Victor Chiosini; Alex Isidório Prado; Bruna Gehlen; Fabio Fernandes Morato Castro; Myrthes Toledo Barros; Jorge Kalil; Leonardo Oliveira Mendonça
Resumo
As síndromes autoinflamatórias associadas à criopirina (CAPS) compreendem um grupo espectral de doenças raras autoinflamatórias. Todas estas doenças estão relacionadas ao inflamassoma NLRP3, sendo que de 50-60% dos pacientes apresentam mutações ao longo do gene NLRP3. Clinicamente, febre recorrente associada à urticária neutrofílica e outros sintomas sistêmicos são o grande marco clínico, comum a todo o espectro. O bloqueio da interleucina-1 trouxe grande alívio ao tratamento destas desordens, mas variações na resposta clínica podem ser observadas, principalmente nos espectros mais graves. Neste trabalho os autores trazem uma revisão do estado da arte das doenças autoinflamatórias CAPS. Foi realizado levantamento de literatura e, ao final, 49 artigos restaram como base para construção do texto final. O trabalho traz de forma narrativa os principais pontos relacionados a imunofisiopatologia, manifestação clínica, diagnóstico, tratamento, complicações e novas armas diagnósticas, e terapia gênica.
Palavras-chave
Abstract
Cryopyrin-associated periodic syndromes (CAPS) comprise a spectrum of rare autoinflammatory disorders. They are all related to the NLRP3 inflammasome, and 50-60% of the patients harbor mutations along the NLRP3 gene. Clinically, recurrent fever associated with neutrophilic urticaria and other systemic symptoms are a hallmark of all the disorders in the spectrum. Biologic drugs that can block interleukin-1 were a milestone for the treatment of such rare diseases, although variability in clinical response to this therapeutic intervention were observed, especially in those affected by severe phenotypes. In this paper, the authors provide a state-of-the-art review of CAPS. A literature search was performed and, finally, 49 articles remained for the construction of the final manuscript. The article presents a narrative review focused on the topics related to immune pathophysiology, clinical manifestations, diagnosis, treatment, complications and new therapeutic options, and gene therapy
Keywords
Referências
1. Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep. 2011;11(1):12-20. doi: 10.1007/s11882-010-0160-9.
2. Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol. 2019;39(3):277-286. doi: 10.1007/s10875-019-00638-z.
3. Xia X, Dai C, Zhu X, Liao Q, Luo X, Fu Y, et al. Identification of a Novel NLRP12 Non-sense Mutation (Trp408X) in the Extremely Rare Disease FCAS by Exome Sequencing. PLoS One. 2016;11(6):e0156981. doi: 10.1371/journal.pone.0156981.
4. Jéru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, LackmyPort-Lis M, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA. 2008;105(5):1614-9. doi: 10.1073/pnas.0708616105.
5. Jeskey J, Parida A, Graven K, Hostoffer R. Novel gene deletion in NLRC4 expanding the familial cold inflammatory syndrome phenotype. Allergy Rhinol (Providence). 2020;11:2152656720928062. doi: 10.1177/2152656720928062.
6. de Torre-Minguela C, Mesa Del Castillo P, Pelegrín P. The NLRP3 and Pyrin Inflammasomes: Implications in the pathophysiology of autoinflammatory diseases. Front Immunol. 2017;8:43. doi: 10.3389/ fimmu.2017.00043.
7. Xiao J, Wang C, Yao JC, Alippe Y, Xu C, Kress D, et al. Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice. PLoS Biol. 2018;16(11):e3000047. doi: 10.1371/journal.pbio.3000047.
8. Carta S, Penco F, Lavieri R, Martini A, Dinarello CA, Gattorno M, et al. Cell stress increases ATP release in NLRP3 inflammasomemediated autoinflammatory diseases, resulting in cytokine imbalance. Proc Natl Acad Sci USA. 2015;112(9):2835-40. doi: 10.1073/pnas.1424741112.
9. Lu A, Wu H. Structural mechanisms of inflammasome assembly. FEBS J. 2015;282(3):435-44. doi: 10.1111/febs.13133.
10. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407-20. doi: 10.1038/nri.2016.58.
11. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature. 2012;481(7381):278-86. doi: 10.1038/nature10759.
12. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677-87. doi: 10.1038/nm.3893.
13. Campbell L, Raheem I, Malemud CJ, Askari AD. The Relationship between NALP3 and Auto-inflammatory Syndromes. Int J Mol Sci. 2016;17(5):725. doi: 10.3390/ijms17050725.
14. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008;58(8):2432-42. doi: 10.1002/art.23620.
15. Stych B, Dobrovolny D. Familial cold autoinflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives. Curr Med Res Opin. 2008;24(6):1577-82. doi: 10.1185/03007990802081543.
16. Hedrich CM, Bruck N, Paul D, Hahn G, Gahr M, Rösen-Wolff A. Mutation negative familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies. Rheumatol Int. 2012;32(9):2629-36. doi: 10.1007/s00296-011-2019-3.
17. Kitley JL, Lachmann HJ, Pinto A, Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology. 2010;74(16):1267-70. doi: 10.1212/WNL.0b013e3181d9ed69.
18. Biswas D, Stafford N. Otolaryngological manifestations of 'MuckleWells syndrome'. Int J Pediatr Otorhinolaryngol. 2010;74(5):553-5. doi: 10.1016/j.ijporl.2010.02.023.
19. Koitschev A, Gramlich K, Hansmann S, Benseler S, Plontke SK, Koitschev C, et al. Progressive familial hearing loss in MuckleWells syndrome. Acta Otolaryngol. 2012;132(7):756-62. doi: 10.3109/00016489.2012.656321.
20. Headley AP, Cordingley F, Hawkins PN, Riminton DS. Muckle-Wells cryopyrinopathy: complex phenotyping and response to therapy in a new multiplex kindred. Inflammation. 2014;37(2):396-401. doi: 10.1007/s10753-013-9752-6.
21. Thomas J, Maramattom BV. Muckle-Wells syndrome associated with multifocal clinically isolated syndrome. Int J Rheum Dis. 2014;17(3):349-50. doi: 10.1111/1756-185X.12317.
22. Tran TA, Koné-Paut I, Marie I, Ninet J, Cuisset L, Meinzer U. Muckle-Wells syndrome and male hypofertility: a case series. Semin Arthritis Rheum. 2012;42(3):327-31. doi: 10.1016/j. semarthrit.2012.03.005.
23. Finetti M, Omenetti A, Federici S, Caorsi R, Gattorno M. Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review. Orphanet J Rare Dis. 2016;11(1):167. doi: 10.1186/s13023-016-0542-8.
24. Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and fiveyear outcomes. Arthritis Rheum. 2012;64(7):2375-86. doi: 10.1002/art.34409.
25. Navallas M, Inarejos Clemente EJ, Iglesias E, Rebollo-Polo M, Zaki FM, Navarro OM. Autoinflammatory diseases in childhood, part 1: monogenic syndromes. Pediatr Radiol. 2020 Mar;50(3):415‑30. doi: 10.1007/s00247-019-04536-9.
26. Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep. 2011;13(2):123-31. doi: 10.1007/s11926-011-0165-y.
27. Paccaud Y, Berthet G, Von Scheven-Gête A, Vaudaux B, Mivelaz Y, Hofer M, et al. Neonatal treatment of CINCA syndrome. Pediatr Rheumatol Online J. 2014;12:52. doi: 10.1186/1546-0096-12-52.
28. Almeida de Jesus A, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol. 2013;147(3):155-74. doi: 10.1016/j.clim.2013.03.016.
29. Sarrabay G, Grandemange S, Touitou I. Diagnosis of cryopyrinassociated periodic syndrome: challenges, recommendations and emerging concepts. Expert Rev Clin Immunol. 2015;11(7):827-35. doi: 10.1586/1744666X.2015.1047765.
30. Johnstone RF, Dolen WK, Hoffman HM. A large kindred with familial cold autoinflammatory syndrome. Ann Allergy Asthma Immunol. 2003;90(2):233-7. doi: 10.1016/S1081-1206(10)62147-3.
31. Nakanishi H, Prakash P, Ito T, Kim HJ, Brewer CC, Harrow D, et al. Genetic hearing loss associated with autoinflammation. Front Neurol. 2020;11:141. doi: 10.3389/fneur.2020.00141.
32. Sag E, Bilginer Y, Ozen S. Autoinflammatory diseases with periodic fevers. Curr Rheumatol Rep. 2017;19(7):41. doi: 10.1007/s11926-017-0670-8.
33. Marzano AV, Tavecchio S, Venturini M, Sala R, Calzavara-Pinton P, Gattorno M. Urticarial vasculitis and urticarial autoinflammatory syndromes. G Ital Dermatol Venereol. 2015;150(1):41-50.
34. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301-5. doi: 10.1038/ng756.
35. Tanaka N, Izawa K, Saito MK, Sakuma M, Oshima K, Ohara O, et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum. 2011;63(11):3625-32. doi: 10.1002/art.30512.
36. Bachove I, Chang C. Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes. Open Access Rheumatol. 2014;6:15-25. doi: 10.2147/OARRR.S46017.
37. Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrinassociated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011;13(6):R202. doi: 10.1186/ar3535.
38. Chang Z, Spong CY, Jesus AA, Davis MA, Plass N, Stone DL, et al. Anakinra use during pregnancy in patients with cryopyrinassociated periodic syndromes (CAPS). Arthritis Rheumatol. 2014;66(11):3227‑32. doi: 10.1002/art.38811.
39. Hawkins PN, Bybee A, Aganna E, McDermott MF. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 2004;50(8):2708-9. doi: 10.1002/art.20357.
40. Rigante D, Leone A, Marrocco R, Laino ME, Stabile A. Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA). Rheumatol Int. 2011;31(12):1661-4. doi: 10.1007/s00296-010-1787-5.
41. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25(6):469-84. doi: 10.1016/j.smim.2013.10.008.
42. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrinassociated periodic syndrome. N Engl J Med. 2009;360(23):2416-25. doi: 10.1056/NEJMoa0810787.
43. Kuemmerle-Deschner JB, Ramos E, Blank N, Roesler J, Felix SD, Jung T, et al. Canakinumab (ACZ885, a fully human IgG1 antiIL-1 mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther. 2011;13(1):R34. doi: 10.1186/ar3266.
44. Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Insalaco A, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther. 2013;15(1):R33. doi: 10.1186/ ar4184.
45. Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012;34(10):2091- 103. doi: 10.1016/j.clinthera.2012.09.009.
46. Landmann EC, Walker UA. Pharmacological treatment options for cryopyrin-associated periodic syndromes. Expert Rev Clin Pharmacol. 2017;10(8):855-64. doi: 10.1080/17512433.2017.1338946.
47. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008;58(8):2432-42. doi: 10.1002/art.23620.
48. Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248-55. doi: 10.1038/nm.3806.
49. van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med. 2005;5(3):87-98. doi: 10.1007/s10238-005-0071-6.
Submetido em:
07/03/2021
Aceito em:
25/04/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email